NEW YORK (GenomeWeb News) – Tegal said after the close of the market yesterday that it has received approval from its shareholders to change the name of the firm to CollabRx.

The name change comes a couple of months after Tegal completed its purchase of genomics data analysis firm CollabRx for an undisclosed amount. At the time, Tegal had said that it would ask its shareholders to approve the name change.

As of tomorrow, the firm's shares will trade on the Nasdaq under the ticker symbol CLRX.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.